Real-world data on clinical outcomes and validation of prognostic models for angioimmunoblastic T-cell lymphoma: a multicentric retrospective study in Southern China
BackgroundThis study aimed to elucidate the treatment outcomes and prognosis of angioimmunoblastic T-cell lymphoma (AITL) patients in a real-world setting.ObjectivesThe clinical efficacy of new drug applications was evaluated, alongside the predictive accuracy of prognostic models, to inform future...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-06-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1580370/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849725971733676032 |
|---|---|
| author | Qiu-Yuan Xiang Jing-Song Wu Ling Huang Zong-Kai Zou Ting-Bo Liu Zhi-Gang Peng Li-E. Lin Xiao-Lei Wei Hong-Yu Zhang Yun Lin Guo-Wei Li Yi-Rong Jiang Hua Wang Ke-Qian Shi Rui-Ji Zheng Zhi-Jun Han Xiao Qiu Wen-Yu Li Ji-Hao Zhou |
| author_facet | Qiu-Yuan Xiang Jing-Song Wu Ling Huang Zong-Kai Zou Ting-Bo Liu Zhi-Gang Peng Li-E. Lin Xiao-Lei Wei Hong-Yu Zhang Yun Lin Guo-Wei Li Yi-Rong Jiang Hua Wang Ke-Qian Shi Rui-Ji Zheng Zhi-Jun Han Xiao Qiu Wen-Yu Li Ji-Hao Zhou |
| author_sort | Qiu-Yuan Xiang |
| collection | DOAJ |
| description | BackgroundThis study aimed to elucidate the treatment outcomes and prognosis of angioimmunoblastic T-cell lymphoma (AITL) patients in a real-world setting.ObjectivesThe clinical efficacy of new drug applications was evaluated, alongside the predictive accuracy of prognostic models, to inform future research.MethodsIn this study, 82.9% of patients received a CHOP-like regimen, while 36.4% also received chidamide. We assessed the prognostic models’ predictive power using the Cox proportional hazards model and concordance index (C-index).ResultsThe median age of the patients in this study was 62.0 years, with 2-year progression-free survival (PFS) and overall survival (OS) rates of 36.1% and 60.3%, respectively. Complete response (CR) rates in first-line treatments were 21.6% for the chidamide-containing group and 28.1% for the chidamide-free group. The AITL scores, PIAI scores, and Chinese AITL scores demonstrated superior C-index values, with the Chinese AITL score providing the most distinct risk stratification. Advanced age (over 70 years), bone marrow involvement, and CD7 negativity were identified as significant prognostic factors associated with poorer PFS in both univariate and multivariate analyses. A novel prognostic model, the South China AITL Score, was constructed by combining these three factors, stratifying patients into low-risk and high-risk groups, with 5-year PFS rates of 81.5% and 34.6%, respectively. This model was successfully validated in an independent cohort.ConclusionsThe prognosis of AITL in real-world settings is poor, and the addition of chidamide did not show improvement in remission rates or survival. Our novel prognostic model, along with the Chinese AITL score, may enhance the identification of Chinese patients at varying risks for chemotherapy. Furthermore, the pathological marker CD7 is anticipated to emerge as a significant biomarker for the prognostic evaluation of AITL. |
| format | Article |
| id | doaj-art-45fc870c95ec4d009e19103693d53b0e |
| institution | DOAJ |
| issn | 2234-943X |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-45fc870c95ec4d009e19103693d53b0e2025-08-20T03:10:20ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-06-011510.3389/fonc.2025.15803701580370Real-world data on clinical outcomes and validation of prognostic models for angioimmunoblastic T-cell lymphoma: a multicentric retrospective study in Southern ChinaQiu-Yuan Xiang0Jing-Song Wu1Ling Huang2Zong-Kai Zou3Ting-Bo Liu4Zhi-Gang Peng5Li-E. Lin6Xiao-Lei Wei7Hong-Yu Zhang8Yun Lin9Guo-Wei Li10Yi-Rong Jiang11Hua Wang12Ke-Qian Shi13Rui-Ji Zheng14Zhi-Jun Han15Xiao Qiu16Wen-Yu Li17Ji-Hao Zhou18Department of Hematology, The Second Clinical Medical College of Jinan University, Shenzhen, ChinaDepartment of Hematology, The Second Clinical Medical College of Jinan University, Shenzhen, ChinaDepartment of Lymphoma, Guangdong Provincial People’s Hospital, Guangdong Academy of Medicine Sciences, Southern Medial University, Guangzhou, ChinaDepartment of Pathology, Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou, Fujian, ChinaDepartment of Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory of Hematology, Fujian Medical University Union Hospital, Fuzhou, ChinaDepartment of Hematology, First Affiliated Hospital of Guangxi Medical University, Nanning, ChinaDepartment of Hematology, Hainan General Hospital, Hainan Affiliated Hospital of Hainan Medical University, Haikou, ChinaDepartment of Hematology, Nanfang Hospital and Southern Medical University, Guangzhou, ChinaDepartment of Hematology, Peking University Shenzhen Hospital, Shenzhen, ChinaDepartment of Hematology, Fujian Provincial Hospital, Fuzhou, China0Department of Hematology, Huizhou Central People’s Hospital, Huizhou, China1Department of Hematology, Affiliated Dongguan People’s Hospital, Southern Medical University (Dongguan People’s Hospital), Dongguan, China2Department of Hematology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, China3Department of Hematology, The First People’s Hospital of Yunnan Province, Kunming, China4Department of Hematology, Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou, Fujian, China4Department of Hematology, Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou, Fujian, China5Department of Hematology, Shenzhen People’s Hospital (The Second Clinical Medical College of Jinan University; The First Affiliated Hospital of Southern University of Science and Technology), Shenzhen, China6Department of Hematology, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China5Department of Hematology, Shenzhen People’s Hospital (The Second Clinical Medical College of Jinan University; The First Affiliated Hospital of Southern University of Science and Technology), Shenzhen, ChinaBackgroundThis study aimed to elucidate the treatment outcomes and prognosis of angioimmunoblastic T-cell lymphoma (AITL) patients in a real-world setting.ObjectivesThe clinical efficacy of new drug applications was evaluated, alongside the predictive accuracy of prognostic models, to inform future research.MethodsIn this study, 82.9% of patients received a CHOP-like regimen, while 36.4% also received chidamide. We assessed the prognostic models’ predictive power using the Cox proportional hazards model and concordance index (C-index).ResultsThe median age of the patients in this study was 62.0 years, with 2-year progression-free survival (PFS) and overall survival (OS) rates of 36.1% and 60.3%, respectively. Complete response (CR) rates in first-line treatments were 21.6% for the chidamide-containing group and 28.1% for the chidamide-free group. The AITL scores, PIAI scores, and Chinese AITL scores demonstrated superior C-index values, with the Chinese AITL score providing the most distinct risk stratification. Advanced age (over 70 years), bone marrow involvement, and CD7 negativity were identified as significant prognostic factors associated with poorer PFS in both univariate and multivariate analyses. A novel prognostic model, the South China AITL Score, was constructed by combining these three factors, stratifying patients into low-risk and high-risk groups, with 5-year PFS rates of 81.5% and 34.6%, respectively. This model was successfully validated in an independent cohort.ConclusionsThe prognosis of AITL in real-world settings is poor, and the addition of chidamide did not show improvement in remission rates or survival. Our novel prognostic model, along with the Chinese AITL score, may enhance the identification of Chinese patients at varying risks for chemotherapy. Furthermore, the pathological marker CD7 is anticipated to emerge as a significant biomarker for the prognostic evaluation of AITL.https://www.frontiersin.org/articles/10.3389/fonc.2025.1580370/fullangioimmunoblastic T-cell lymphoma (AITL)prognostic modelclinical characteristicssurvival ratereal-world studySouth China AITL score |
| spellingShingle | Qiu-Yuan Xiang Jing-Song Wu Ling Huang Zong-Kai Zou Ting-Bo Liu Zhi-Gang Peng Li-E. Lin Xiao-Lei Wei Hong-Yu Zhang Yun Lin Guo-Wei Li Yi-Rong Jiang Hua Wang Ke-Qian Shi Rui-Ji Zheng Zhi-Jun Han Xiao Qiu Wen-Yu Li Ji-Hao Zhou Real-world data on clinical outcomes and validation of prognostic models for angioimmunoblastic T-cell lymphoma: a multicentric retrospective study in Southern China Frontiers in Oncology angioimmunoblastic T-cell lymphoma (AITL) prognostic model clinical characteristics survival rate real-world study South China AITL score |
| title | Real-world data on clinical outcomes and validation of prognostic models for angioimmunoblastic T-cell lymphoma: a multicentric retrospective study in Southern China |
| title_full | Real-world data on clinical outcomes and validation of prognostic models for angioimmunoblastic T-cell lymphoma: a multicentric retrospective study in Southern China |
| title_fullStr | Real-world data on clinical outcomes and validation of prognostic models for angioimmunoblastic T-cell lymphoma: a multicentric retrospective study in Southern China |
| title_full_unstemmed | Real-world data on clinical outcomes and validation of prognostic models for angioimmunoblastic T-cell lymphoma: a multicentric retrospective study in Southern China |
| title_short | Real-world data on clinical outcomes and validation of prognostic models for angioimmunoblastic T-cell lymphoma: a multicentric retrospective study in Southern China |
| title_sort | real world data on clinical outcomes and validation of prognostic models for angioimmunoblastic t cell lymphoma a multicentric retrospective study in southern china |
| topic | angioimmunoblastic T-cell lymphoma (AITL) prognostic model clinical characteristics survival rate real-world study South China AITL score |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2025.1580370/full |
| work_keys_str_mv | AT qiuyuanxiang realworlddataonclinicaloutcomesandvalidationofprognosticmodelsforangioimmunoblastictcelllymphomaamulticentricretrospectivestudyinsouthernchina AT jingsongwu realworlddataonclinicaloutcomesandvalidationofprognosticmodelsforangioimmunoblastictcelllymphomaamulticentricretrospectivestudyinsouthernchina AT linghuang realworlddataonclinicaloutcomesandvalidationofprognosticmodelsforangioimmunoblastictcelllymphomaamulticentricretrospectivestudyinsouthernchina AT zongkaizou realworlddataonclinicaloutcomesandvalidationofprognosticmodelsforangioimmunoblastictcelllymphomaamulticentricretrospectivestudyinsouthernchina AT tingboliu realworlddataonclinicaloutcomesandvalidationofprognosticmodelsforangioimmunoblastictcelllymphomaamulticentricretrospectivestudyinsouthernchina AT zhigangpeng realworlddataonclinicaloutcomesandvalidationofprognosticmodelsforangioimmunoblastictcelllymphomaamulticentricretrospectivestudyinsouthernchina AT lielin realworlddataonclinicaloutcomesandvalidationofprognosticmodelsforangioimmunoblastictcelllymphomaamulticentricretrospectivestudyinsouthernchina AT xiaoleiwei realworlddataonclinicaloutcomesandvalidationofprognosticmodelsforangioimmunoblastictcelllymphomaamulticentricretrospectivestudyinsouthernchina AT hongyuzhang realworlddataonclinicaloutcomesandvalidationofprognosticmodelsforangioimmunoblastictcelllymphomaamulticentricretrospectivestudyinsouthernchina AT yunlin realworlddataonclinicaloutcomesandvalidationofprognosticmodelsforangioimmunoblastictcelllymphomaamulticentricretrospectivestudyinsouthernchina AT guoweili realworlddataonclinicaloutcomesandvalidationofprognosticmodelsforangioimmunoblastictcelllymphomaamulticentricretrospectivestudyinsouthernchina AT yirongjiang realworlddataonclinicaloutcomesandvalidationofprognosticmodelsforangioimmunoblastictcelllymphomaamulticentricretrospectivestudyinsouthernchina AT huawang realworlddataonclinicaloutcomesandvalidationofprognosticmodelsforangioimmunoblastictcelllymphomaamulticentricretrospectivestudyinsouthernchina AT keqianshi realworlddataonclinicaloutcomesandvalidationofprognosticmodelsforangioimmunoblastictcelllymphomaamulticentricretrospectivestudyinsouthernchina AT ruijizheng realworlddataonclinicaloutcomesandvalidationofprognosticmodelsforangioimmunoblastictcelllymphomaamulticentricretrospectivestudyinsouthernchina AT zhijunhan realworlddataonclinicaloutcomesandvalidationofprognosticmodelsforangioimmunoblastictcelllymphomaamulticentricretrospectivestudyinsouthernchina AT xiaoqiu realworlddataonclinicaloutcomesandvalidationofprognosticmodelsforangioimmunoblastictcelllymphomaamulticentricretrospectivestudyinsouthernchina AT wenyuli realworlddataonclinicaloutcomesandvalidationofprognosticmodelsforangioimmunoblastictcelllymphomaamulticentricretrospectivestudyinsouthernchina AT jihaozhou realworlddataonclinicaloutcomesandvalidationofprognosticmodelsforangioimmunoblastictcelllymphomaamulticentricretrospectivestudyinsouthernchina |